🔎 Trials Near Me

Akèy › Kansè ovè › Illinois

Etid klinik pou Kansè ovè nan Illinois

49 etid pou Kansè ovè ap chèche patisipan nan sit nan Illinois.

Vil nan Illinois

Tèks ofisyèl etid la (Anglè)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Advocate Good Shepherd Hospital, Barrington
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • ak 57 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University of Chicago Hospital, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • University of Illinois Cancer Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Rush Md Anderson Cancer Center /ID# 274926, Chicago
  • University of Chicago Medical Center /ID# 274796, Chicago
  • OSF St. Francis Medical Center /ID# 274752, Peoria
  • ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • University of Chicago, Chicago
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05051722

DESTINY-PANTUMOUR04

  • Research Site, Decatur
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 24, 2026 · NCT04590326

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Illinois Cancer Specialists, Arlington Heights
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Northwestern University Feinberg School of Medicine, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • City of Hope, Chicago, Zion
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Illinois Cancer Specialists (ICS) ( Site 8009), Arlington Heights
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • The University of Chicago Medicine, Chicago
  • Carle Cancer Center, Effingham
  • Northshore University Health System-Evanston Hospital, Evanston
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • University of Chicago, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT06787612

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • University of Illinois Cancer Center, Chicago
  • University of Chicago Medicine, Chicago
  • City of Hope - Chicago, Zion
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • University of Chicago, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT04107077

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Lurie Children's Hospital-Chicago, Chicago
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Northwestern Medicine Cancer Center Old Irving Park, Chicago
  • ak 5 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07001748

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • St. Francis Medical Center (OSF Healthcare), Peoria
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07470853

A Study of PHST001 in Advanced Solid Tumors

  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06840886

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  • Research Site, Chicago
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Advocate Outpatient Center - Aurora, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • Carle BroMenn Outpatient Center, Bloomington
  • ak 35 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • OSF Saint Anthony's Health Center, Alton
  • Rush-Copley Medical Center, Aurora
  • Advocate Outpatient Center - Aurora, Aurora
  • ak 58 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • St. Francis Medical Center (OSF Healthcare), Peoria
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Orchard Healthcare Research Inc, Skokie
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Hope and Healing Cancer Services, Hinsdale
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

  • Rush University Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Jul 23, 2026 · NCT03854110

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

  • The University of Chicago Medical Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT04918186

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

  • Northwestern Memorial Hospital, Chicago
Ap rekriteFaz 2
Laj 18 a 100 · Fanm · Mizajou Jul 13, 2026 · NCT05887609

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Ingalls Family Care Center, Calumet City
  • UChicago Medicine - River East, Chicago
  • The University Of Chicago, Chicago
  • ak 13 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Endeavor Health Evanston Kellogg Cancer Care Center, Evanston
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007

Integrated Cancer Repository for Cancer Research

  • Rush-Copley Cancer Care Center, Aurora
  • Rush-Copley Healthcare Center, Yorkville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Northwestern University, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

  • GSK Investigational Site, Harvey
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04641247

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

  • Northwestern University, Chicago
Ap rekrite
Laj 60 ak plis · Fanm · Mizajou May 29, 2026 · NCT05743517

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

  • OSF Saint Francis Medical Center, Peoria
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou May 28, 2026 · NCT06930755

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

  • University of Chicago Medical Center, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT03686124

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  • UChicago Medicine, Chicago
Ap rekrite
Laj 25 a 50 · Fanm · Mizajou Apr 6, 2026 · NCT04294927

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.